Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

(2013) Elisabeth I. Heath et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

QT interval prolongation and the risk of torsades de pointes: essentials for clinicians

(2013) Katy E. Trinkley et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

(2013) Rashmi R. Shah et al.   DRUG SAFETY

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes

(2013) Kimberly R. Doherty et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Blocking of the Human Ether-^|^agrave;-go-go-Related Gene Channel by Imatinib Mesylate

(2012) Qian Dong et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience

(2012) Erkan Dogan et al.   MEDICAL ONCOLOGY

Electrophysiological Effects of the Anti-Cancer Drug Lapatinib on Cardiac Repolarization

(2010) Hyang-Ae Lee et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

(2010) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Drug-Induced QT-Interval Prolongation: Considerations for Clinicians

(2010) Edward C Li et al.   PHARMACOTHERAPY

Cardiac Ion Channels

(2009) Augustus O. Grant   Circulation-Arrhythmia and Electrophysiology

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

(2009) C. L. Bello et al.   CLINICAL CANCER RESEARCH

Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts

(2009) Richard Kobza et al.   HEART RHYTHM

QTc prolongation and/or oncology drug development: Who’s in danger?

(2008) Maja de Jonge et al.   EUROPEAN JOURNAL OF CANCER

Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development

(2007) Giuseppe Curigliano et al.   EUROPEAN JOURNAL OF CANCER